PhaseBio Pharmaceuticals Depreciation & Amortization Growth

Depreciation & Amortization Growth of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Depreciation & Amortization Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Depreciation & Amortization Growth for the quarter ending June 29, 2021 was 922.81% (a 18.65% increase compared to previous quarter)
  • Year-over-year quarterly Depreciation & Amortization Growth increased by 9128.1%
  • Annual Depreciation & Amortization Growth for 2020 was 191.95% (a 192.12% increase from previous year)
  • Annual Depreciation & Amortization Growth for 2019 was 65.71% (a 600.53% increase from previous year)
  • Annual Depreciation & Amortization Growth for 2018 was 9.38% (a 115.63% increase from previous year)
  • Twelve month Depreciation & Amortization Growth ending June 29, 2021 was 589.1% (a 58.76% increase compared to previous quarter)
  • Twelve month trailing Depreciation & Amortization Growth increased by 1155.01% year-over-year
Trailing Depreciation & Amortization Growth for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
589.1% 371.07% 191.95% 46.94%
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Depreciation & Amortization Growth of PhaseBio Pharmaceuticals

Most recent Depreciation & Amortization Growthof PHAS including historical data for past 10 years.

Interactive Chart of Depreciation & Amortization Growth of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Depreciation & Amortization Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 922.81% 777.78%
2020 584.0% 10.0% 32.56% 74.19% 191.95%
2019 117.39% 78.57% 59.26% 14.81% 65.71%
2018 -17.86% -58.82% 9.38%
2017 4.35%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.